What's Happening?
Amylyx Pharmaceuticals has reported its financial results for the fourth quarter and full year of 2025, highlighting significant progress in its avexitide program for post-bariatric hypoglycemia (PBH). The company has completed recruitment for its Phase
3 LUCIDITY trial, which aims to evaluate the efficacy and safety of avexitide in PBH patients. The trial is expected to provide topline data by the third quarter of 2026. Avexitide, a glucagon-like peptide-1 receptor antagonist, has shown promise in reducing hypoglycemic events in previous trials. Amylyx is preparing for potential commercialization of avexitide in 2027, supported by a cash runway extending into 2028.
Why It's Important?
The advancement of the avexitide program is crucial for addressing the unmet medical needs of patients with post-bariatric hypoglycemia, a condition affecting a significant number of individuals who have undergone bariatric surgery. If successful, avexitide could become the first FDA-approved therapy for PBH, offering a new treatment option for patients experiencing debilitating hypoglycemic events. The progress in the LUCIDITY trial and the company's financial stability position Amylyx to potentially bring this innovative treatment to market, improving the quality of life for affected individuals.
What's Next?
Amylyx plans to complete the enrollment and dosing of participants in the LUCIDITY trial by the end of the first quarter of 2026, with topline data expected in the third quarter. The company is also preparing for a regulatory submission and building its commercial infrastructure to support the potential launch of avexitide in 2027. Additionally, Amylyx is advancing other investigational therapies, including AMX0114 for amyotrophic lateral sclerosis, with ongoing clinical trials and expected data presentations in 2026.
